Dosulepin is an older prescription antidepressant, also called dothiepin. Confidence is high for its identity; this guide explains restricted prescribing, safety and withdrawal without claiming comparative treatment superiority. NLM identity.
- England policy advises against starting dosulepin; existing treatment needs a planned review.
- Suspected overdose requires immediate emergency assessment, even if the person seems well.
- Heart disease, other medicines and pregnancy or feeding plans need individual prescribing review.
- Do not abruptly stop treatment or attempt a switch using an internet dose schedule.
- Dispensing counts show continued use; they do not make dosulepin a preferred medicine.
Table of contents
- Evidence summary
- Dosulepin, dothiepin and Prothiaden: what the names mean
- Dosulepin’s pharmacology
- Why dosulepin prescribing is restricted
- Depression care and St John’s wort: alternatives need their own review
- What the human research can and cannot establish
- Dosulepin side effects and overdose
- Dosulepin interactions and serotonin syndrome
- Dosulepin, mania, pregnancy and breastfeeding
- Taking and stopping dosulepin
- Laboratory evidence, commercial claims and suspected-event reporting
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Why prioritise this medicine? | England PCA workbook. | NHSBSA public/service income; allocation unclosed. | Items, not worldwide use or efficacy. |
| Should new treatment be started routinely? | Label and England policy. | Maker 4/D; public-policy allocation unclosed. | Restricted licence and no-initiation policy; planned review. |
| What does human safety research show? | Original observational methods/declarations. | No external funding reported; institutional finance unclosed. | No personal mortality estimate or causal comparison. |
| Can herbs or a home taper replace care? | NCCIH and SPS context. | Public/gift routes; exact contributors and trials unclosed. | No product endorsement or personal regimen. |
Dosulepin, dothiepin and Prothiaden: what the names mean
NLM’s vocabulary groups dosulepin and Prothiaden under dothiepin, a tricyclic antidepressant. These are aliases for this medicine scope, not separate evidence pages. Brand availability and formulation still require checking against the actual pack. Official vocabulary.
England recorded 264,876 dosulepin hydrochloride community prescription items in FY 2025/26, BNF 0403010J0. Original substance table.
PCA counts England community dispensing, including hospital-issued prescriptions dispensed there; hospital dispensary supplies are excluded. Items are not unique people, tablets or treatment indications. These statistics do not establish worldwide popularity, personal benefit or appropriateness. Original definitions.
Dosulepin’s pharmacology
The label describes monoamine reuptake inhibition, including noradrenaline and serotonin, plus anticholinergic and antihistamine effects. Product mechanism.
For this review, a mechanism is not accepted as comparative outcome evidence. We ask separately whether a human study measures the outcome of interest, whether its population is relevant, how its design limits inference and who financed it. A promising biological explanation does not complete that clinical and financial audit.
Why dosulepin prescribing is restricted
For depressive symptoms, the UK label restricts use because of overdose toxicity to intolerance or nonresponse to alternatives, with new starts under specialist care. It does not recommend children’s use. Current licensed role.
NHS England policy says not to initiate dosulepin and to review existing treatment for deprescribing. Continued prescribing requires no appropriate available alternative and multidisciplinary discussion. The exact indexed policy section was read; its full direct page was unavailable. Policy context.
Ask the prescriber why it remains on the prescription, which previous options were tried, what the agreed treatment aims are and who owns the next review. Bring the actual pack and an accurate treatment history. A dispensing record alone cannot answer those questions.
Depression care and St John’s wort: alternatives need their own review
The committee-authored NG222 summary describes shared decisions across psychological, behavioural and medicine options, matched to severity and preferences. It is attributed depression-care guidance; the full current committee register and underlying trial financial chains were not retrieved. No dosulepin benefit estimate is inferred from that framework. Author summary.
St John’s wort can interact harmfully with medicines, including antidepressants. Its components and interactions do not make it a predictable dosulepin substitute. This review does not endorse adding it, using it as a withdrawal aid or adopting the supplement efficacy claims without an original trial-funding audit. NCCIH safety account.
Ask about access to talking treatment and practical support alongside the medicine review. Which options address the diagnosed problem, and how are they coordinated? A coherent care plan should not depend on interpreting “natural” as a safety guarantee or buying an unreviewed herbal brand.
What the human research can and cannot establish
Gray and colleagues studied prescribing and poisoning records in England and Wales using 2016–2020 data. Their observational analysis links aggregate dispensing with poison enquiries, hospital episodes and deaths. Incomplete capture, multiple-drug poisonings and an item denominator limit personal or causal comparisons; no mortality ratio is reproduced here. Original human study.
This article establishes neither a conflict-cleared benefit magnitude nor a ranking of dosulepin against every antidepressant. That limitation concerns this audit; it does not prove that an individual has received no benefit. A useful clinical review can take a person’s experience seriously while also recognising that perceived improvement, prescribing volume, regulatory permission and an independently funded comparative trial answer different questions. Manufacturer efficacy tables and untraced underlying trials are excluded from the independent verdict.
Dosulepin side effects and overdose
The leaflet lists drowsiness, dry mouth, constipation, blurred vision, dizziness and urinary difficulty. Suspected overdose, including a child swallowing tablets, requires immediate emergency assessment without waiting for symptoms. Safety leaflet.
SPS advises generally avoiding TCAs in coronary disease because of conduction, rhythm and blood-pressure effects and overdose toxicity. Some diuretics add electrolyte-related risk. Existing heart disease needs an individual review; this is not a home ECG interpretation rule. Heart-disease guidance.
New self-harm or suicidal thoughts need immediate contact with the care team. If you cannot stay safe, seek emergency help using the local emergency number. Young adults and people with previous suicidal thoughts need particular attention. NHS safety advice.
A routine appointment cannot replace emergency assessment after suspected poisoning.
Dosulepin interactions and serotonin syndrome
MAOIs/recent MAOI treatment are contraindicated; concurrent SSRIs should be avoided. Inform the anaesthesia team before procedures. Label interactions.
SPS warns that combined or sequential antidepressants can cause serotonin syndrome. Fever or marked sweating with agitation/confusion and tremor, rigidity or jerking needs urgent assessment, particularly after a medicine change. Review plans should also cover withdrawal and early worsening; younger adults or suicide risk require closer follow-up. Switch safety guidance.
Use the appointment to agree who maintains the medicine list and communicates changes between services. Ask who checks a new prescription and whom to contact with questions. This guide supplies no complete checker, safe washout interval or instruction to overlap antidepressants.
Alcohol can worsen drowsiness. Do not drive or use machinery until you know how treatment affects you. Leaflet precautions.
Dosulepin, mania, pregnancy and breastfeeding
Recent heart attack, heart block/arrhythmias, mania and severe liver disease are contraindications. Pregnancy requires compelling justification. Epilepsy, narrow-angle glaucoma and urinary retention also require review. Contraindications and pregnancy.
The SPS TCA breastfeeding guidance covers full-term healthy infants and does not provide a dosulepin-specific entry. It cannot establish that this medicine is safe for every infant. Pregnancy, premature or unwell infants, other medicines and feeding plans need specialist reconciliation with the actual label. Breastfeeding scope.
Seek prompt review for severe excitement or marked mood changes. Leaflet review advice.
Taking and stopping dosulepin
Check pack instructions with the pharmacist; never double a missed dose. Store securely away from children. Pack instructions.
NHS guidance advises against abrupt antidepressant stopping. Withdrawal can be severe, delayed or prolonged and can resemble returning illness. A prescriber should assess the pattern rather than assuming every symptom is relapse or that withdrawal must resolve on a fixed timetable. Withdrawal guidance.
SPS describes deprescribing as a shared, tolerable reduction when treatment is unsuitable or the person wants review. Previous withdrawal difficulty matters; the plan may need a longer pace and follow-up. No percentage reduction or fixed taper is provided here. Deprescribing context.
SPS switching strategies depend on both medicines and the person’s symptoms. Overlap, stopping and washout are different professional decisions, not interchangeable internet schedules. A prescriber or specialist pharmacist should specify the plan and responsibility for monitoring. Switching framework.
Useful questions are: Who can I contact between appointments? What changes should I report promptly? What happens if symptoms become difficult or a refill is delayed? Which service owns the next review? Confirm the written instructions with the dispensing pharmacy if the pack or strength changes. This article does not tell you to split, crush, reduce, replace or restart tablets and does not recommend a personal dose.
Laboratory evidence, commercial claims and suspected-event reporting
Animal and cell experiments may investigate mechanisms but cannot establish clinical benefit for a person taking dosulepin. They are excluded from this guide’s treatment verdict. Independently established comparative benefit requires an original human evidence and financial audit; neither a mechanism nor a prescribing count completes that task.
MHRA’s Yellow Card service accepts suspected adverse-effect reports. A report need not prove causation; reporting also does not replace medical assessment. Counts from voluntary reports cannot supply a reliable risk rate for an individual. Safety-reporting service.
Every source below has a defined role. Finance records can identify an agency’s income or a supplier’s ownership without proving that a particular webpage was paid for by that funder. Unknown allocation remains a gap. The same standard applies to public, academic and commercial institutions; an institutional name does not settle the independence of the underlying medicine trials.
Funding and source roles
Research funding at a glance
29 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NLM Dothiepin / dosulepin vocabulary | NLM budget; Gift authority. Exact entry allocation and contributor interests unclosed. | United States; Bethesda NIH. | Tier 2; public taxonomy, provisional | B provisional. Identity and aliases, not treatment outcomes. |
| Sovereign SmPC, August 2026 | Waymade PLC t/a Sovereign Medical. Supplier identity. | United Kingdom; Basildon authorisation holder. | Tier 4; manufacturer source | D. Commercial safety source; efficacy excluded. |
| Sovereign leaflet, February 2024 | Waymade/Sovereign supplier-authored; Commercial route. | United Kingdom. | Tier 4; manufacturer source | D. Pack instructions and warnings, not comparative benefit. |
| NHS England dosulepin policy | Commissioner accounts. Authors, exact allocation and underlying trial interests unclosed. | England; NHS policy. | Tier 2; public policy, access-limited | C provisional. Indexed original dosulepin section read; full direct page unavailable. |
| SPS antidepressants and coronary disease | Service route. Host accounts, authors, exact allocation and trial interests unclosed. | United Kingdom; distributed NHS service. | Tier 2; clinical context, provisional | B provisional. April 2025; no independent drug-outcome clearance. |
| SPS switch monitoring | Service route. Host accounts, authors, exact allocation and trial interests unclosed. | United Kingdom; distributed NHS service. | Tier 2; clinical context, provisional | B provisional. September 2024 update; no independent drug-outcome clearance. |
| SPS switching strategies | Service route. Host accounts, authors, exact allocation and trial interests unclosed. | United Kingdom; distributed NHS service. | Tier 2; clinical context, provisional | B provisional. May 2024; no independent drug-outcome clearance. |
| SPS antidepressant deprescribing | Service route. Host accounts, authors, exact allocation and trial interests unclosed. | United Kingdom; distributed NHS service. | Tier 2; clinical context, provisional | B provisional. January 2026 title update; 2023 body; no independent drug-outcome clearance. |
| SPS TCA breastfeeding | Service route. Host accounts, authors, exact allocation and trial interests unclosed. | United Kingdom; distributed NHS service. | Tier 2; clinical context, provisional | B provisional. November 2023; no independent drug-outcome clearance. |
| NHS antidepressants, June 2025 | Website funding policy. Contributor and original trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public safety context, provisional | B provisional. Class education, not a dosulepin efficacy review. |
| NG222 author summary, 2022 | NICE funded UCL guideline work; Eadon: NICE employment. Kendrick: NIHR; Pilling: MRC; Kapur: NIHR, DHSC and charities. NICE accounts. | United Kingdom authors. | Tier 2; commissioned framework, provisional | B provisional. No specific summary-writing funding reported; full committee register and trial chains unclosed. |
| Gray et al. poisoning study, 2025 | Authors report no external project funding or competing interests. Institutional salaries and data-service finance not fully traced. | United Kingdom; England/Wales analysis. | Tier 1; declared independent research, provisional | B provisional. Observational methods; incomplete capture and aggregate denominators limit inference. |
| NCCIH St John’s wort, May 2025 | Federal route; Gift authority. Exact page payments, contributors and underlying trials unclosed. | United States; Bethesda NIH. | Tier 2; public safety context, provisional | B provisional. Interaction education, no independent supplement efficacy clearance. |
| MHRA Yellow Card | Regulator accounts. Exact service and contributor allocation unclosed. | United Kingdom; MHRA. | Tier 3; regulatory/reporting context, provisional | B provisional. Suspected reports support surveillance, not incidence or causation. |
| Waymade own company description | Generic/niche pharmaceutical development, licensing and commercialisation. Registry control. | United Kingdom; Monarch House, Basildon. | Tier 4; seller financial source | D. Own commercial description; no independent efficacy role. Full accounts not retrieved. |
| Waymade register of control | Vijaykumar Chhotabhai Kalidas Patel reported with 75%+ shares/votes and director-appointment power. | United Kingdom company register. | Tier 3; company-filed financial record, provisional | B provisional. Filing-based identity; registry does not check all reported information. |
| Waymade filing history, July 2026 | 2025 group accounts filed 8 July 2026. Register read; linked full accounts unavailable. | United Kingdom company register. | Tier 3; company-filed financial record, access-limited | C provisional. No account totals, full revenue ledger or product allocation inferred. |
| PCA antidepressant substance data, FY 2025/26 | NHSBSA accounts. Programme staffing and exact allocation unclosed. | England community dispensing. | Tier 2; public statistics, provisional | B provisional. Actual workbook read; item count is not clinical quality. |
| PCA methodology, June 2026 | Agency finance. Exact statistical programme allocation unclosed. | United Kingdom; England dataset. | Tier 2; public definitions, provisional | B provisional. Coverage and unit definitions, not drug outcomes. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC website funding stated; no advertising/corporate sponsorship; contributor declarations required. Policy reviewed 2022, review due 2025. | United Kingdom; national NHS website. | Tier 3; own policy | B provisional. Public accountability; overdue policy review and public contributor-register gaps. No trial clearance. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; individual page allocations unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| NICE accounts, 2025/26 | Mainly DHSC grant-in-aid; NHS England support, appraisal/advice fees, research and other income. Exact NG222 allocation unclosed. | United Kingdom; Manchester report contact, London office. | Tier 3; own financial report | B provisional. Statutory accountability and assessment-income incentives; not committee/trial clearance. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NCCIH budget explanation | HHS/NIH Congressional appropriations route. FY 2025 request documents explicitly no longer reflect current budget policy; current enacted page allocation unverified. | United States; Bethesda, Maryland. | Tier 3; own budget statement | B provisional. Funding mechanism verified, no request treated as enacted/current spending. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NCCIH/NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
| NLM FY 2027 justification | FY 2026 enacted funding distinguished from FY 2027 request. Institutional grants/contracts/intramural routes; MeSH allocation and individual gifts unclosed. | United States; Bethesda NIH library. | Tier 3; own budget report | B provisional. Selected actual budget table read; institutional money does not clear contributor interests. |
| NLM appropriations index | Congressional justification index; 2026 consolidation described as a proposal. Current 2027 original separately read above. | United States; 8600 Rockville Pike, Bethesda. | Tier 3; own institution record | B provisional. Location/index only; no completed restructuring inferred. |
Frequently asked questions
Are dosulepin and dothiepin different medicines? They are aliases for the same medicine scope. NLM vocabulary.
Does continued prescribing mean dosulepin is preferred? No. England’s policy advises against initiation; existing prescriptions require a planned clinical review. Policy context.
Can I stop dosulepin because of the prescribing restriction? Agree a withdrawal plan with the prescriber; a restriction is not an instruction to stop abruptly. SPS guidance.
Does general TCA breastfeeding advice clear dosulepin? No. The SPS page has no dosulepin-specific entry and its scope is full-term healthy infants. Scope limits.
Does this guide prove dosulepin works better than other antidepressants? No independently cleared comparative benefit estimate is supplied. This audit limit is not proof that an individual’s prescribed treatment has provided no benefit.
Sources and funding notes
Sovereign label: 7 August 2026; leaflet: February 2024. NHS England’s exact indexed dosulepin policy section was available, but the complete direct page was not. The full NG222 committee register was unavailable; the actual author-summary proof and its funding declarations were read. Waymade’s current business, ownership and filing records were read; its linked full group accounts were not retrieved. Whole institutional reports were not claimed as read. Dated policy, service-contract and NCCIH request gaps are retained. Underlying treatment-trial financial chains remain unclosed; no independent comparative efficacy estimate is adopted. Brand names are aliases, not verification of every country’s supplier or formulation.
- NLM Dothiepin / dosulepin vocabulary — Medicine identity
- Sovereign SmPC, August 2026 — Product safety
- Sovereign leaflet, February 2024 — Patient leaflet
- NHS England dosulepin policy — No-initiation policy
- SPS antidepressants and coronary disease — Specialist care context
- SPS switch monitoring — Specialist care context
- SPS switching strategies — Specialist care context
- SPS antidepressant deprescribing — Specialist care context
- SPS TCA breastfeeding — Specialist care context
- NHS antidepressants, June 2025 — Class safety
- NG222 author summary, 2022 — Attributed depression care
- Gray et al. poisoning study, 2025 — Human safety research
- NCCIH St John’s wort, May 2025 — Herbal safety
- MHRA Yellow Card — Adverse-event reporting
- Waymade own company description — Supplier business route
- Waymade register of control — Recorded ownership
- Waymade filing history, July 2026 — Financial access gap
- PCA antidepressant substance data, FY 2025/26 — Prescribing prioritisation
- PCA methodology, June 2026 — Dataset limits
- NHSBSA accounts, 2025/26 — Institutional finance
- NHS content policy — Dated website funding policy
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- NICE accounts, 2025/26 — Guideline institution finance
- MHRA accounts, 2025/26 — Safety regulator finance
- NCCIH budget explanation — Federal institution route
- NIH gift-administration policy — Gift authority, not receipt
- NLM FY 2027 justification — Taxonomy institution finance
- NLM appropriations index — Institution location and budget provenance
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.